Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Seeking Alpha
MZE829 targets APOL1-mediated kidney disease with a dual inhibition strategy, potentially surpassing Vertex's first-mover approach; Phase 2 HORIZON data is expected in Q1 FY2026. MAZE's pipeline includes MZE782 for phenylketonuria and CKD, plus a promising 'skinny gene' obesity program targeting nutrient absorption. Strategic asset monetization and recent equity raises provide a cash runway into FY2028, minimizing near-term dilution risk. Solskin/DigitalVision via Getty Images Intro Maze Therapeutics ( MAZE ) is helping fill a fundamental inefficiency in current drug development. Genome-Wide Association Studies can identify thousands of loci associated with common diseases; however, the industry has often struggled to convert these signals into This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of MAZE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opin
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% [Yahoo! Finance]Yahoo! Finance
- Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
MAZE
Earnings
- 11/6/25 - Beat
MAZE
Sec Filings
- 1/16/26 - Form 144
- 1/9/26 - Form 4
- 1/8/26 - Form 4
- MAZE's page on the SEC website